GTC Case Study Series

uniQure Hemgenix Case Study

A strategic analysis of uniQure's Hemgenix (etranacogene dezaparvovec) — from regulatory pathway to the $3.5M price tag. Key lessons on the avoidable hurdles in development, approval, and commercialisation.

rAAV5 · Haemophilia B Commercial Intelligence

Get the free case study

6 chapters dissecting the Hemgenix programme

From the regulatory strategy that secured FDA approval to the commercial outcomes after launch — including what developers and investors can replicate.

Chapter 1 uniQure & Hemgenix: Company Overview and Programme History
Chapter 2 Regulatory Strategy: FDA Approval Pathway and EMA Authorisation
Chapter 3 Manufacturing Scale-Up: From Clinical Batches to Commercial Supply
Chapter 4 Pricing & Reimbursement: How a $3.5M Therapy Gets to Market
Chapter 5 Commercial Outcomes: What the Hemgenix Launch Actually Achieved
Chapter 6 Key Lessons for Gene Therapy Developers and Investors

Get the full case study — free

Complete the form below and download the uniQure Hemgenix Case Study instantly — no waiting.

I am

Private Expert / Individual Corporate Representative

Your expertise / focus area

How did you hear about us? (optional)

Your download has started

If it doesn’t start within a few seconds, click here to download.

Join the GTC Expert Network to access all resources in one place →

uniQure Hemgenix Case Study

6 chapters dissecting the Hemgenix programme

Get the full case study — free

Your download has started

Remove the avoidable hurdles before they cost you